LY-344864

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H22FN3O
Molecular Weight	351.4173
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(NC(=O)C4=CC=C(F)C=C4)=C3

InChI

InChIKey=GKWHICIUSVVNGX-MRXNPFEDSA-N

InChI=1S/C21H22FN3O/c1-25(2)16-8-10-20-18(12-16)17-11-15(7-9-19(17)24-20)23-21(26)13-3-5-14(22)6-4-13/h3-7,9,11,16,24H,8,10,12H2,1-2H3,(H,23,26)/t16-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C21H22FN3O
Molecular Weight	351.4173
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9395253

LY344864 is a selective 5-HT1F receptor agonist (EC50 = 3 nM). In a rat model of migraine, LY344864 inhibited neurogenic dural inflammation following i.v. and oral administration.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
5-hydroxytryptamine receptor 1F 8 Target ID: P30939 Gene ID: 3355.0 Gene Symbol: HTR1F Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/9395253	Agonist 2678		6.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Migraine 103 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9395253	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine.	1997	9395253

Patents

Sample Use Guides

In Vivo Use Guide

LY344864 dose-dependently inhibited neurogenic dural inflammation in the rat when administered by the intravenous (0.2-2 ng/kg) or oral (1-10 ng/kg) routes.

Route of Administration: Other

In Vitro Use Guide

LY344864 inhibited the forskolin-induced accumulation of cyclic AMP in LM(tk-) cells stably transfected with the human 5-HT1F receptor demonstrating an EC50 of 3 nM and a maximum inhibition equal to 98.5% of that produced by serotonin itself.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 08:14:06 GMT 2023` Edited by `admin` on `Sat Dec 16 08:14:06 GMT 2023`
Record UNII	L4WN6HH63L
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LY-344864

Code

English

BENZAMIDE, N-((3R)-3-(DIMETHYLAMINO)-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-6-YL)-4-FLUORO-

Systematic Name

English

(R)-N-(3-(DIMETHYLAMINO)-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-6-YL)-4-FLUOROBENZAMIDE

Systematic Name

English

LY344864

Code

English

BENZAMIDE, N-(3-(DIMETHYLAMINO)-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-6-YL)-4-FLUORO-, (R)-

Systematic Name

English

Code System Code Type Description

CAS

186544-26-3

Created by admin on Sat Dec 16 08:14:06 GMT 2023 , Edited by admin on Sat Dec 16 08:14:06 GMT 2023

PRIMARY

EPA CompTox

DTXSID201134040

Created by admin on Sat Dec 16 08:14:06 GMT 2023 , Edited by admin on Sat Dec 16 08:14:06 GMT 2023

PRIMARY

FDA UNII

L4WN6HH63L

Created by admin on Sat Dec 16 08:14:06 GMT 2023 , Edited by admin on Sat Dec 16 08:14:06 GMT 2023

PRIMARY

PUBCHEM

5311097

Created by admin on Sat Dec 16 08:14:06 GMT 2023 , Edited by admin on Sat Dec 16 08:14:06 GMT 2023

PRIMARY

Related Record Type Details


					L4WN6HH63L

LY-344864

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/9395253

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9395253